Skip to main content
Top
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Parkinson's Disease | Study Protocol

The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson’s Disease (randomized controlled trial)

Authors: Sabine Schootemeijer, Nienke M. de Vries, Eric A. Macklin, Kit C.B. Roes, Hilde Joosten, Larsson Omberg, Alberto Ascherio, Michael A. Schwarzschild, Bastiaan R. Bloem

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Exercise has various health benefits for people with Parkinson’s disease (PD). However, implementing exercise into daily life and long-term adherence remain challenging. To increase a sustainable engagement with physical activity of people with PD, interventions that are motivating, accessible, and scalable are needed. We primarily aim to investigate whether a smartphone app (STEPWISE app) can increase physical activity (i.e., step count) in people with PD over one year. Our second aim is to investigate the potential effects of the intervention on physical fitness, and motor- and non-motor function. Our third aim is to explore whether there is a dose-response relationship between volume of physical activity and our secondary endpoints.

Methods

STEPWISE is a double-blind, randomized controlled trial. We aim to include 452 Dutch people with PD who can walk independently (Hoehn & Yahr stages 1–3) and who do not take more than 7,000 steps per day prior to inclusion. Physical activity levels are measured as step counts on the participant’s own smartphone and scaled as percentage of each participant’s baseline. Participants are randomly assigned to an active control group with an increase of 5–20% (active controls) or any of the three intervention arms with increases of 25–100% (intermediate dose), 50–200% (large dose), or 100–400% (very large dose). The primary endpoint is change in step count as measured by the STEPWISE smartphone app from baseline to 52 weeks. For our primary aim, we will evaluate the between-group difference in average daily step count change from baseline to 52 weeks. For our second aim, measures of physical fitness, and motor- and non-motor function are included. For our third aim, we will associate 52-week changes in step count with 52-week changes in secondary outcomes.

Discussion

This trial evaluates the potential of a smartphone-based intervention to increase activity levels in people with PD. We envision that motivational apps will increase adherence to physical activity recommendations and could permit conduct of remote clinical trials of exercise for people with PD or those at risk of PD.

Trial registration

ClinicalTrials.gov; NCT04848077; 19/04/2021. Clinicaltrials.gov/ct2/show/NCT04848077.
Literature
1.
go back to reference Feigin VL, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80.CrossRef Feigin VL, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80.CrossRef
2.
go back to reference Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet, 2021. Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet, 2021.
3.
go back to reference Schenkman M, et al. Effect of high-intensity Treadmill Exercise on Motor symptoms in patients with De Novo Parkinson Disease: a phase 2 Randomized Clinical Trial. JAMA Neurol. 2018;75(2):219–26.CrossRefPubMed Schenkman M, et al. Effect of high-intensity Treadmill Exercise on Motor symptoms in patients with De Novo Parkinson Disease: a phase 2 Randomized Clinical Trial. JAMA Neurol. 2018;75(2):219–26.CrossRefPubMed
4.
go back to reference van der Kolk NM, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trial. The Lancet Neurology; 2019. van der Kolk NM, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trial. The Lancet Neurology; 2019.
5.
go back to reference Petzinger GM, et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol. 2013;12(7):716–26.CrossRefPubMedPubMedCentral Petzinger GM, et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol. 2013;12(7):716–26.CrossRefPubMedPubMedCentral
6.
go back to reference Johansson ME, et al. Aerobic Exercise alters brain function and structure in Parkinson’s Disease: a Randomized Controlled Trial. Ann Neurol. 2022;91(2):203–16.CrossRefPubMedPubMedCentral Johansson ME, et al. Aerobic Exercise alters brain function and structure in Parkinson’s Disease: a Randomized Controlled Trial. Ann Neurol. 2022;91(2):203–16.CrossRefPubMedPubMedCentral
7.
go back to reference Schootemeijer S et al. Current Perspectives on Aerobic Exercise in People with Parkinson’s Disease. Neurotherapeutics. 2020;17(4):1418–1433. Schootemeijer S et al. Current Perspectives on Aerobic Exercise in People with Parkinson’s Disease. Neurotherapeutics. 2020;17(4):1418–1433.
8.
go back to reference Fang X, et al. Association of levels of physical activity with risk of Parkinson Disease: a systematic review and Meta-analysis. JAMA Netw Open. 2018;1(5):e182421.CrossRefPubMedPubMedCentral Fang X, et al. Association of levels of physical activity with risk of Parkinson Disease: a systematic review and Meta-analysis. JAMA Netw Open. 2018;1(5):e182421.CrossRefPubMedPubMedCentral
9.
go back to reference Yoon SY, et al. Lifestyle factors and Parkinson Disease Risk: korean Nationwide Cohort Study with repeated Health Screening Data. Neurology. 2022;98(6):e641–52.CrossRefPubMed Yoon SY, et al. Lifestyle factors and Parkinson Disease Risk: korean Nationwide Cohort Study with repeated Health Screening Data. Neurology. 2022;98(6):e641–52.CrossRefPubMed
10.
go back to reference Bull FC, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451–62.CrossRefPubMed Bull FC, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451–62.CrossRefPubMed
12.
go back to reference Warmerdam E, et al. Long-term unsupervised mobility assessment in movement disorders. The Lancet Neurology; 2020. Warmerdam E, et al. Long-term unsupervised mobility assessment in movement disorders. The Lancet Neurology; 2020.
14.
go back to reference Ellis TD, et al. Comparative effectiveness of mhealth-supported Exercise compared with Exercise alone for people with Parkinson Disease: Randomized Controlled Pilot Study. Phys Ther. 2019;99(2):203–16.CrossRefPubMed Ellis TD, et al. Comparative effectiveness of mhealth-supported Exercise compared with Exercise alone for people with Parkinson Disease: Randomized Controlled Pilot Study. Phys Ther. 2019;99(2):203–16.CrossRefPubMed
15.
go back to reference Yerrakalva D, et al. Effects of Mobile Health App Interventions on Sedentary Time, Physical Activity, and fitness in older adults: systematic review and Meta-analysis. J Med Internet Res. 2019;21(11):e14343.CrossRefPubMedPubMedCentral Yerrakalva D, et al. Effects of Mobile Health App Interventions on Sedentary Time, Physical Activity, and fitness in older adults: systematic review and Meta-analysis. J Med Internet Res. 2019;21(11):e14343.CrossRefPubMedPubMedCentral
16.
go back to reference Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.CrossRefPubMed Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.CrossRefPubMed
17.
18.
go back to reference Bloem BR, et al. Measurement instruments to assess posture, gait, and balance in Parkinson’s disease: Critique and recommendations. Mov Disord. 2016;31(9):1342–55.CrossRefPubMed Bloem BR, et al. Measurement instruments to assess posture, gait, and balance in Parkinson’s disease: Critique and recommendations. Mov Disord. 2016;31(9):1342–55.CrossRefPubMed
19.
go back to reference Shulman LM, et al. Disability rating Scales in Parkinson’s Disease: Critique and Recommendations. Mov Disord. 2016;31(10):1455–65.CrossRefPubMed Shulman LM, et al. Disability rating Scales in Parkinson’s Disease: Critique and Recommendations. Mov Disord. 2016;31(10):1455–65.CrossRefPubMed
20.
go back to reference Goetz CG, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRefPubMed Goetz CG, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRefPubMed
21.
go back to reference Skorvanek M, et al. Global scales for cognitive screening in Parkinson’s disease: Critique and recommendations. Mov Disord. 2018;33(2):208–18.CrossRefPubMed Skorvanek M, et al. Global scales for cognitive screening in Parkinson’s disease: Critique and recommendations. Mov Disord. 2018;33(2):208–18.CrossRefPubMed
22.
go back to reference BV C. Castor Electronic Data capture. Amsterdam; 2016. BV C. Castor Electronic Data capture. Amsterdam; 2016.
23.
go back to reference Yardley L, et al. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing. 2005;34(6):614–9.CrossRefPubMed Yardley L, et al. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing. 2005;34(6):614–9.CrossRefPubMed
24.
go back to reference Jonasson SB, Nilsson MH, Lexell J. Psychometric properties of the original and short versions of the Falls Efficacy Scale-International (FES-I) in people with Parkinson’s disease. Health Qual Life Outcomes. 2017;15(1):116.CrossRefPubMedPubMedCentral Jonasson SB, Nilsson MH, Lexell J. Psychometric properties of the original and short versions of the Falls Efficacy Scale-International (FES-I) in people with Parkinson’s disease. Health Qual Life Outcomes. 2017;15(1):116.CrossRefPubMedPubMedCentral
25.
go back to reference Stel VS, et al. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. J Clin Epidemiol. 2004;57(3):252–8.CrossRefPubMed Stel VS, et al. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. J Clin Epidemiol. 2004;57(3):252–8.CrossRefPubMed
26.
go back to reference Bosscher RJ, et al. Physical performance and physical self-efficacy in the Elderly:a pilot study. J Aging Health. 1995;7(4):459–75.CrossRefPubMed Bosscher RJ, et al. Physical performance and physical self-efficacy in the Elderly:a pilot study. J Aging Health. 1995;7(4):459–75.CrossRefPubMed
28.
go back to reference Leentjens AF, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2015–25.CrossRefPubMed Leentjens AF, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2015–25.CrossRefPubMed
29.
go back to reference Stankevich Y, et al. Psychometric Properties of an Abbreviated Version of the apathy evaluation scale for Parkinson Disease (AES-12PD). Am J Geriatr Psychiatry. 2018;26(10):1079–90.CrossRefPubMed Stankevich Y, et al. Psychometric Properties of an Abbreviated Version of the apathy evaluation scale for Parkinson Disease (AES-12PD). Am J Geriatr Psychiatry. 2018;26(10):1079–90.CrossRefPubMed
30.
go back to reference Friedman JH, et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord. 2010;25(7):805–22.CrossRefPubMed Friedman JH, et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord. 2010;25(7):805–22.CrossRefPubMed
31.
go back to reference Hogl B, et al. Scales to assess sleep impairment in Parkinson’s disease: critique and recommendations. Mov Disord. 2010;25(16):2704–16.CrossRef Hogl B, et al. Scales to assess sleep impairment in Parkinson’s disease: critique and recommendations. Mov Disord. 2010;25(16):2704–16.CrossRef
32.
go back to reference Evatt ML, et al. Dysautonomia rating scales in Parkinson’s disease: sialorrhea, dysphagia, and constipation–critique and recommendations by movement disorders task force on rating scales for Parkinson’s disease. Mov Disord. 2009;24(5):635–46.CrossRefPubMedPubMedCentral Evatt ML, et al. Dysautonomia rating scales in Parkinson’s disease: sialorrhea, dysphagia, and constipation–critique and recommendations by movement disorders task force on rating scales for Parkinson’s disease. Mov Disord. 2009;24(5):635–46.CrossRefPubMedPubMedCentral
33.
go back to reference Martinez-Martin P, et al. Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(13):2371–80.CrossRefPubMed Martinez-Martin P, et al. Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(13):2371–80.CrossRefPubMed
34.
go back to reference Keus S, et al. European physiotherapy guideline for Parkinson’s disease. The Netherlands: KNGF/ParkinsonNet; 2014. Keus S, et al. European physiotherapy guideline for Parkinson’s disease. The Netherlands: KNGF/ParkinsonNet; 2014.
35.
go back to reference Omberg L et al. Remote smartphone monitoring of Parkinson’s disease and individual response to therapy. Nat Biotechnol, 2022;40(4):480–487. Omberg L et al. Remote smartphone monitoring of Parkinson’s disease and individual response to therapy. Nat Biotechnol, 2022;40(4):480–487.
36.
go back to reference Webster DE et al. Heart Snapshot: a broadly validated smartphone measure of VO < sub > 2 max for collection of real world data bioRxiv, 2020: p. 2020.07.02.185314. Webster DE et al. Heart Snapshot: a broadly validated smartphone measure of VO < sub > 2 max for collection of real world data bioRxiv, 2020: p. 2020.07.02.185314.
37.
go back to reference Vorrink SN, et al. Efficacy of an mHealth intervention to stimulate physical activity in COPD patients after pulmonary rehabilitation. Eur Respir J. 2016;48(4):1019–29.CrossRefPubMed Vorrink SN, et al. Efficacy of an mHealth intervention to stimulate physical activity in COPD patients after pulmonary rehabilitation. Eur Respir J. 2016;48(4):1019–29.CrossRefPubMed
38.
40.
go back to reference Nijkrake MJ, et al. The ParkinsonNet concept: development, implementation and initial experience. Mov Disord. 2010;25(7):823–9.CrossRefPubMed Nijkrake MJ, et al. The ParkinsonNet concept: development, implementation and initial experience. Mov Disord. 2010;25(7):823–9.CrossRefPubMed
41.
go back to reference Tanner CM, et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. NPJ Parkinsons Dis. 2021;7(1):16.CrossRefPubMedPubMedCentral Tanner CM, et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. NPJ Parkinsons Dis. 2021;7(1):16.CrossRefPubMedPubMedCentral
42.
go back to reference Speelman AD, et al. Evaluation of implementation of the ParkFit program: a multifaceted intervention aimed to promote physical activity in patients with Parkinson’s disease. Physiotherapy. 2014;100(2):134–41.CrossRefPubMed Speelman AD, et al. Evaluation of implementation of the ParkFit program: a multifaceted intervention aimed to promote physical activity in patients with Parkinson’s disease. Physiotherapy. 2014;100(2):134–41.CrossRefPubMed
43.
go back to reference de Vries NM, Darweesh SKL, Bloem BR. Citius, Fortius, Altius-Understanding which Components Drive Exercise benefits in Parkinson Disease. JAMA Neurol. 2021;78(12):1443–5.CrossRefPubMed de Vries NM, Darweesh SKL, Bloem BR. Citius, Fortius, Altius-Understanding which Components Drive Exercise benefits in Parkinson Disease. JAMA Neurol. 2021;78(12):1443–5.CrossRefPubMed
44.
go back to reference van Nimwegen M, et al. Promotion of physical activity and fitness in sedentary patients with Parkinson’s disease: randomised controlled trial. BMJ. 2013;346:f576.CrossRefPubMedPubMedCentral van Nimwegen M, et al. Promotion of physical activity and fitness in sedentary patients with Parkinson’s disease: randomised controlled trial. BMJ. 2013;346:f576.CrossRefPubMedPubMedCentral
45.
go back to reference Ypinga JHL, et al. Rationale and design to evaluate the PRIME Parkinson care model: a prospective observational evaluation of proactive, integrated and patient-centred Parkinson care in the Netherlands (PRIME-NL). BMC Neurol. 2021;21(1):286.CrossRefPubMedCentral Ypinga JHL, et al. Rationale and design to evaluate the PRIME Parkinson care model: a prospective observational evaluation of proactive, integrated and patient-centred Parkinson care in the Netherlands (PRIME-NL). BMC Neurol. 2021;21(1):286.CrossRefPubMedCentral
46.
go back to reference Bloem BR, et al. The personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease. BMC Neurol. 2019;19(1):160.CrossRefPubMedPubMedCentral Bloem BR, et al. The personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease. BMC Neurol. 2019;19(1):160.CrossRefPubMedPubMedCentral
47.
go back to reference Munneke M, et al. Efficacy of community-based physiotherapy networks for patients with Parkinson’s disease: a cluster-randomised trial. Lancet Neurol. 2010;9(1):46–54.CrossRefPubMed Munneke M, et al. Efficacy of community-based physiotherapy networks for patients with Parkinson’s disease: a cluster-randomised trial. Lancet Neurol. 2010;9(1):46–54.CrossRefPubMed
48.
go back to reference Tsukita K, Sakamaki-Tsukita H, Takahashi R. Long-term effect of regular physical activity and Exercise Habits in patients with early Parkinson Disease. Neurology. 2022;98(8):e859–71.CrossRefPubMedPubMedCentral Tsukita K, Sakamaki-Tsukita H, Takahashi R. Long-term effect of regular physical activity and Exercise Habits in patients with early Parkinson Disease. Neurology. 2022;98(8):e859–71.CrossRefPubMedPubMedCentral
49.
50.
go back to reference Silva AG et al. Mobile apps to quantify aspects of physical activity: a systematic review on its reliability and validity. J Med Syst, 2020. 44(2). Silva AG et al. Mobile apps to quantify aspects of physical activity: a systematic review on its reliability and validity. J Med Syst, 2020. 44(2).
Metadata
Title
The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson’s Disease (randomized controlled trial)
Authors
Sabine Schootemeijer
Nienke M. de Vries
Eric A. Macklin
Kit C.B. Roes
Hilde Joosten
Larsson Omberg
Alberto Ascherio
Michael A. Schwarzschild
Bastiaan R. Bloem
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03355-8

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue